Vistagen Therapeutics announced a roughly 20% workforce reduction on March 5, 2026, to cut costs and prioritize resources for its social anxiety nasal spray, fasedienol. This restructuring aims to extend the company’s cash runway while advancing its ongoing pipeline, specifically the PALISADE-4 Phase 3 trial.
https://uk.investing.com/news/sec-filings/vistagen-therapeutics-reduces-workforce-by-20-percent-to-manage-costs-93CH-4552464